ViroStatics
Desconocido
THUNDER: Development of the Cyclin Dependent Kinase Inhibitor VS2 370 to Target HIV associated Malignancies a...
VIROSTATICS SRL
tramitó un
H2020:
H2020-SMEInst-2016-2017
ViroStatics, operating in the biotechnology industry, is developing the innovative drug VS2-370 that targets both HIV-associated cancer and...
2017-02-04 - 2017-07-31 | Financiado
2017-02-04 - 2017-07-31 | Financiado
THINPAD: Targeting the HIV 1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance
VIROSTATICS SRL
participó en un
FP7:
AIDS is one of the most serious pandemic diseases of the modern era. Although current therapies based on targeting key processes of the HIV...
Financiado
Financiado
* No se disponen de datos de la empresa actual.